N2OFF rebrands to Nexentis Technologies, shifts focus to AI-driven mitochondrial biotech

Nexentis Technologies Inc.

Name change to Nexentis Technologies Inc. and ticker change to NXTS effective Feb 26, 2026.
Rebranding reflects integration of MitoCareX Bio with MITOLINE platform targeting mitochondrial SLC25 carriers.
Recent in vitro data showed anti-tumor activity and reduction in pro-inflammatory markers.
Company continues to manage RTB solar energy investments as non-core asset base.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Nexentis Technologies Inc.: Certificate of Amendment to Articles of Incorporation filed to change corporate name to Nexentis Technologies Inc (effective 2026-02-26).

Change: charter amendment
Effective: 2026-02-26

Exact text from the filing

The Board of Directors of N2OFF, Inc., a Nevada corporation (the “Company”) approved on January 26, 2026 the change in the name of the Company to “Nexentis Technologies Inc.” (the “Name Change”) and the change in the trading symbol of the Company to “NXTS” on the Nasdaq Capital Market (the “Symbol Change”). To effectuate the Name Change, the Company filed a Certificate of Amendment to the Articles of Incorporation of the Company, as amended (the “Charter Amendment”) with the Secretary of State of the State of Nevada. The Name Change and the Symbol Change will take effect on the Nasdaq Capital Market on February 26, 2026.

View on SEC.gov

40 governance changes filed in the last 30 days. Browse all governance changes →

Nexentis Technologies Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-007988

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.